ICIs, such as anti-PD1 and anti-PD-L1 antibodies, have achieved significant efficacy in a variety of cancer treatments, but still face limitations such as mixed efficacy and immune-related side effects, which has driven deeper research to optimize their application and overcome resistance (79–81). Here, CD274 is linked to cancer.